Digestive Diseases Market Analysis and Reports | UK Conference Series

Market Analysis - Digestive Diseases 2020

Description:

Metabolism is a process in which human body generates energy from the food humans eat. The food that humans consume comprises proteinscarbohydrates, and fats. Chemicals in human digestive system break the food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in human body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by enzymes. Any disturbance in the pathways involved in the development and metabolism of carbohydratesproteins, and fats, leads to metabolic disorder.

While in 2015, the market size of metabolic disorder therapeutics was valued over USD XX million. The global metabolic disorder therapeutics market is projected to grow with a CAGR between 4.8% and 5.3% over the forecast period of 2018-2023 and reach USD 200 billion by 2023.

Increase in academia-industry collaborations for drug developments is the key factor responsible for the growth of metabolic disorder therapeutics market. Furthermore, growing diabetic population is significantly contributing to the growth of this market. Low compliance, adherence rate for metabolic disorder therapies and availability of alternative treatment option are the major challenges faced by the players operating in this market. The global metabolic disorder therapeutics market is anticipated to present several opportunities of growth of market size over the forecast period due to strategic collaborations and acquisition and increased R & D investment

The report on global metabolic disorders therapeutics market covers segments such as, disease type and product. On the basis of disease type the global metabolic disorders therapeutics market is categorized into diabetesobesityhypercholesterolemia and lysosomal storage disease. On the basis of product the global metabolic disorders therapeutics market is categorized into metachromatic leukodystrophy, globoid leukodystrophy,hepatic encephalopathy and others.

The report segments the metabolic disorder therapeutics market by types of disease and by region. Among segments given above; diabetes market is estimated to be 24.9 billion USD in 2017, it is growing because of the higher growth in the global type 2 diabetic population. The Oral Anti Diabetes Market is expected to witness a growth of about 28% from 2018 to 2023 and it is expected to reach USD 34.1 billion by 2023.The increasing diabetic population across the globe is one of the significant factors propelling the growth of this segment.